PT1912677E - Conjugados de anticorpos contra psma-fármaco - Google Patents

Conjugados de anticorpos contra psma-fármaco Download PDF

Info

Publication number
PT1912677E
PT1912677E PT67852830T PT06785283T PT1912677E PT 1912677 E PT1912677 E PT 1912677E PT 67852830 T PT67852830 T PT 67852830T PT 06785283 T PT06785283 T PT 06785283T PT 1912677 E PT1912677 E PT 1912677E
Authority
PT
Portugal
Prior art keywords
antibody
psma
drug conjugate
antigen
cell
Prior art date
Application number
PT67852830T
Other languages
English (en)
Portuguese (pt)
Inventor
William C Olson
Paul J Maddon
Peter D Senter
Dangshe Ma
Svetlana O Doronina
Brian E Toki
Original Assignee
Psma Dev Company L L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psma Dev Company L L C filed Critical Psma Dev Company L L C
Publication of PT1912677E publication Critical patent/PT1912677E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT67852830T 2005-06-20 2006-06-20 Conjugados de anticorpos contra psma-fármaco PT1912677E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69239905P 2005-06-20 2005-06-20
US79236006P 2006-04-14 2006-04-14

Publications (1)

Publication Number Publication Date
PT1912677E true PT1912677E (pt) 2013-12-23

Family

ID=37460276

Family Applications (1)

Application Number Title Priority Date Filing Date
PT67852830T PT1912677E (pt) 2005-06-20 2006-06-20 Conjugados de anticorpos contra psma-fármaco

Country Status (14)

Country Link
US (2) US20070160617A1 (cg-RX-API-DMAC7.html)
EP (1) EP1912677B1 (cg-RX-API-DMAC7.html)
JP (3) JP2008546792A (cg-RX-API-DMAC7.html)
KR (3) KR20140084242A (cg-RX-API-DMAC7.html)
CN (2) CN103127523A (cg-RX-API-DMAC7.html)
AU (1) AU2006262231B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0612529A2 (cg-RX-API-DMAC7.html)
CA (1) CA2612762C (cg-RX-API-DMAC7.html)
DK (1) DK1912677T3 (cg-RX-API-DMAC7.html)
ES (1) ES2440482T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ565075A (cg-RX-API-DMAC7.html)
PL (1) PL1912677T3 (cg-RX-API-DMAC7.html)
PT (1) PT1912677E (cg-RX-API-DMAC7.html)
WO (1) WO2007002222A2 (cg-RX-API-DMAC7.html)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US7244827B2 (en) * 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
ES2606537T3 (es) 2001-10-23 2017-03-24 Psma Development Company L.L.C. Anticuerpos contra PSMA
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
KR101438983B1 (ko) 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
CA2680535C (en) 2007-03-14 2016-09-20 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CA2690943A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
JP5469600B2 (ja) 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法
EP2176295B1 (en) 2007-07-16 2014-11-19 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
SI2187965T1 (sl) * 2007-08-17 2020-03-31 Purdue Research Foundation Office Of Technology Commercialization Konjugati vezalca ligand-veznika PSMA in metode za uporabo
WO2009026274A1 (en) * 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
US8039597B2 (en) * 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
ES2643239T3 (es) 2008-01-31 2017-11-21 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
CA2721169A1 (en) * 2008-04-14 2009-10-22 Proscan Rx Pharma Inc. Prostate specific membrane antigen antibodies and antigen binding fragments
DK2291659T3 (en) 2008-05-13 2015-12-21 Univ Yale SMALL CHEMICAL MOLECULES FOR RECRUITING ANTIBODIES TO CANCER CELLS
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
WO2010027513A2 (en) * 2008-09-08 2010-03-11 Psma Development Company, Llc Methods for killing psma-expressing, taxane-resistant cancer cells
US9186336B2 (en) 2009-02-06 2015-11-17 The General Hospital Corporation Methods of treating vascular lesions
EP2403524A4 (en) * 2009-03-06 2012-09-26 Agensys Inc CONJUGATES ANTIBODY-DRUG (ADC) BINDING PROTEINS 24P4C12
JP6046494B2 (ja) * 2010-02-08 2016-12-14 アジェンシス，インコーポレイテッド １６１ｐ２ｆ１０ｂタンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
ES2581314T3 (es) * 2010-03-02 2016-09-05 Seattle Genetics, Inc. Métodos de cribado de anticuerpos
CA2833019A1 (en) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
SG10201605293PA (en) * 2011-05-27 2016-08-30 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US9796754B2 (en) * 2011-05-27 2017-10-24 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
CN104520321A (zh) 2012-01-09 2015-04-15 斯克利普斯研究所 超长互补决定区及其用途
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
SG10201603896RA (en) * 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
DK2858676T3 (da) * 2012-06-07 2019-05-13 Ambrx Inc Prostata-specifikke membran-antigen-antistof-lægemiddelkonjugater
WO2013188740A1 (en) * 2012-06-14 2013-12-19 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
WO2014057114A1 (en) * 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
IN2015DN04147A (cg-RX-API-DMAC7.html) 2012-10-16 2015-10-16 Endocyte Inc
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
BR112015013033A2 (pt) * 2012-12-07 2017-07-11 3M Innovative Properties Co método de fabricação de condutores transparentes sobre substrato
MY183572A (en) 2013-03-15 2021-02-26 Regeneron Pharma Biologically active molecules, conjugates thereof, and therapeutic uses
CN107252485A (zh) * 2013-04-03 2017-10-17 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法
BR112015030514A2 (pt) 2013-06-04 2017-08-29 Cytomx Therapeutics Inc Composições e métodos para conjugação de anticorpos ativáveis
WO2015006736A2 (en) 2013-07-11 2015-01-15 The California Institute For Biomedical Research Coiled coil immunoglobulin fusion proteins and compositions thereof
GEP20237497B (en) 2013-10-18 2023-04-10 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015057250A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
JP6908964B2 (ja) * 2013-10-18 2021-07-28 ピーエスエムエー ディベロップメント カンパニー，エルエルシー Ｐｓｍａリガンドコンジュゲートによる併用療法
US20160287731A1 (en) 2013-11-14 2016-10-06 Endocyte, Inc. Compounds for Positron Emission Tomography
US20150147339A1 (en) 2013-11-15 2015-05-28 Psma Development Company, Llc Biomarkers for psma targeted therapy for prostate cancer
EP3082877B1 (en) 2013-12-17 2019-08-28 Novartis AG Cytotoxic peptides and conjugates thereof
JP6517240B2 (ja) 2014-05-22 2019-05-22 シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． 抗体へのリンカー薬物の部位特異的コンジュゲーションおよび得られるａｄｃ
CN106573956A (zh) 2014-06-13 2017-04-19 诺华股份有限公司 澳瑞他汀衍生物及其缀合物
EP3262071B8 (en) 2014-09-23 2022-05-18 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
JP2017531642A (ja) * 2014-10-03 2017-10-26 マサチューセッツ インスティテュート オブ テクノロジー エボラ糖タンパク質に結合する抗体およびその使用
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
MX386328B (es) 2015-03-27 2025-03-18 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
CN108136042A (zh) * 2015-08-06 2018-06-08 希望之城 治疗性细胞内化缀合物
BR112018005573A2 (pt) 2015-09-21 2019-01-22 Aptevo Research And Development Llc ?polipeptídeos de ligação a cd3?
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
CN116059390A (zh) 2016-03-24 2023-05-05 拜耳制药股份公司 具有酶促可裂解基团的细胞毒性活性物质的前药
US20170296679A1 (en) * 2016-04-18 2017-10-19 Intuitive Surgical Operations, Inc. Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands
MX382216B (es) 2016-06-02 2025-03-13 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
CN109310781B (zh) 2016-06-15 2024-06-18 拜耳制药股份公司 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
KR20190099250A (ko) 2016-12-21 2019-08-26 바이엘 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물
PE20191235A1 (es) 2016-12-21 2019-09-11 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
JP2020505034A (ja) 2017-01-20 2020-02-20 ジュノ セラピューティクス ゲーエムベーハー 細胞表面コンジュゲートならびに関連する細胞組成物および方法
WO2018178277A1 (en) 2017-03-29 2018-10-04 Avicenna Oncology Gmbh New targeted cytotoxic isocombretaquinoline derivatives and conjugates thereof
EP3607319A1 (en) 2017-04-07 2020-02-12 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
WO2018215936A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
JP7224365B2 (ja) * 2017-06-19 2023-02-17 バイリ－バイオ（チェンドゥ）ファーマスーティカル シーオー．，エルティーディー． 酸性自己安定化ジョイントを有する抗体薬物複合体
CN111417410B (zh) 2017-12-01 2023-06-23 艾伯维公司 糖皮质激素受体激动剂及其免疫缀合物
MX2020009842A (es) * 2018-03-23 2020-10-15 Seattle Genetics Inc Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido.
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
JP2021522193A (ja) 2018-04-17 2021-08-30 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 癌を治療する方法
EP3834843A4 (en) 2018-08-06 2022-05-11 Daiichi Sankyo Company, Limited COMBINATION OF ANTIBODY-DRUG CONJUGATE AND TUBULIN INHIBITOR
FR3085952B1 (fr) 2018-09-17 2020-10-30 Centre Nat Rech Scient Conjugue anticorps-medicament comprenant des derives de quinoline
US12473265B2 (en) 2019-05-20 2025-11-18 Endocyte, Inc. Methods for preparing PSMA conjugates
DE102019135564B4 (de) * 2019-12-20 2022-05-19 Johannes-Gutenberg-Universität Mainz Verbindung für Smart-Drug-Delivery und pharmazeutisches Kit für duale nuklearmedizinisch-cytotoxische Theranostik
CA3177279A1 (en) * 2020-03-25 2021-09-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-psma antibody-exatecan analogue conjugate and medical use thereof
EP4228704A1 (en) * 2020-10-18 2023-08-23 Ardeagen Corporation Anti-cspg4 binding agents, conjugates thereof and methods of using the same
US20230414762A1 (en) * 2020-11-17 2023-12-28 The Johns Hopkins University Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma
EP4429654A4 (en) 2021-11-09 2025-07-09 Univ Case Western Reserve PSMA-TARGETED CONJUGATE COMPOUNDS AND THEIR USES
WO2024027795A1 (zh) * 2022-08-04 2024-02-08 苏州开拓药业股份有限公司 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
CN116196428B (zh) * 2023-04-04 2025-04-04 上海愿智生物技术有限公司 一种药物组合物及其应用
TW202521545A (zh) * 2023-08-04 2025-06-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｐｓｍａ抗體－藥物偶聯物及其醫藥用途
WO2025256632A1 (zh) * 2024-06-14 2025-12-18 长春金赛药业有限责任公司 靶向b7-h3和psma的双特异性抗体及抗体-药物偶联物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1019163A (en) * 1963-01-23 1966-02-02 Robert Dorfman A collapsible cap or the like
FR2554327A1 (fr) * 1983-11-03 1985-05-10 Gamerdinger Philippe Chapeau monopiece
JPS61137624U (cg-RX-API-DMAC7.html) * 1985-02-15 1986-08-27
JPS6270126U (cg-RX-API-DMAC7.html) * 1985-10-23 1987-05-02
GB8814827D0 (en) * 1988-06-22 1988-07-27 Caple I Planar article
JPH0460516U (cg-RX-API-DMAC7.html) * 1990-09-27 1992-05-25
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH0712435U (ja) * 1993-07-29 1995-02-28 規子 山内 組み立て帽子セット
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US5804602A (en) * 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
FR2818660B1 (fr) * 2000-12-27 2005-03-11 Agronomique Inst Nat Rech Levures transformees par des genes augmentant leur tolerance au stress froid
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20050215472A1 (en) * 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
ES2606537T3 (es) * 2001-10-23 2017-03-24 Psma Development Company L.L.C. Anticuerpos contra PSMA
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
SI1545613T1 (sl) * 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
WO2004067564A2 (en) * 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
KR101438983B1 (ko) * 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
EP1817336B1 (en) * 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
WO2007008848A2 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
EP1917020B1 (en) * 2005-07-07 2016-05-25 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites

Also Published As

Publication number Publication date
CA2612762A1 (en) 2007-01-04
DK1912677T3 (da) 2014-01-13
CA2612762C (en) 2013-12-10
JP6063747B2 (ja) 2017-01-18
ES2440482T3 (es) 2014-01-29
EP1912677A2 (en) 2008-04-23
KR20150126978A (ko) 2015-11-13
JP2013100314A (ja) 2013-05-23
WO2007002222A2 (en) 2007-01-04
KR20140084242A (ko) 2014-07-04
CN101287498B (zh) 2013-03-27
AU2006262231B2 (en) 2013-01-24
JP2008546792A (ja) 2008-12-25
BRPI0612529A2 (pt) 2010-11-23
AU2006262231A1 (en) 2007-01-04
JP2015187117A (ja) 2015-10-29
WO2007002222A3 (en) 2007-08-09
KR20080031296A (ko) 2008-04-08
CN103127523A (zh) 2013-06-05
US20070160617A1 (en) 2007-07-12
CN101287498A (zh) 2008-10-15
EP1912677B1 (en) 2013-10-02
US20210023094A1 (en) 2021-01-28
NZ565075A (en) 2011-05-27
HK1116697A1 (en) 2009-01-02
PL1912677T3 (pl) 2014-03-31

Similar Documents

Publication Publication Date Title
CA2464239C (en) Psma antibodies and protein multimers
CA2612762C (en) Psma antibody-drug conjugates
US20040161776A1 (en) PSMA formulations and uses thereof
CN101553506B (zh) Lingo结合分子及其制药用途
DK2692865T3 (en) Transponeringsmedieret identification of specific binding proteins, or functional
CN101605899B (zh) 用于大量生产重组蛋白质的新载体和表达细胞系以及使用其生产重组蛋白质的方法
CN101595228A (zh) 包括sorf构建体的多基因表达和使用多蛋白、前体蛋白和蛋白酶解的方法
CN113908291A (zh) 通过序列特异性转肽酶制备免疫配体/效应分子结合物的方法
KR102584628B1 (ko) T-세포 수용체, t-세포 항원 및 이들의 기능성 상호작용의 식별 및 특징규명을 위한 조작된 다성분 시스템
US20240207318A1 (en) Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
JP2025122051A (ja) Ｔ細胞レセプター及びｔ細胞抗原の同定及び特徴決定のための遺伝子操作された多成分システム
KR20230117327A (ko) 가용성 알칼리성 포스파타제 작제물 및 가용성 알칼리성 포스파타제 작제물을 인코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터
KR20240022571A (ko) Rna-가이드된 이펙터 동원을 위한 시스템, 방법 및 성분
KR102393402B1 (ko) 세포 내 존재 단백질과 세포 외부로 분비되는 단백질을 동시 발현하는 이중발현벡터를 포함하는 암의 예방 또는 치료용 조성물
AU775429B2 (en) A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
HK40067445A (en) Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
HK40003571A (en) Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme